C
C2N Diagnostics
Developing innovative diagnostics for Alzheimer's disease and related neurodegenerative conditions
About C2N Diagnostics
C2N Diagnostics is a company focused on the development and commercialization of diagnostics for neurodegenerative conditions, with a primary focus on Alzheimer's disease. The company's core offering is the Precivity™ portfolio of blood tests, including the PrecivityAD™ and PrecivityAD2™ assays. These tests are designed for individuals aged 55 and older who are experiencing cognitive impairment, providing a less invasive and more cost-effective alternative to traditional diagnostic methods like PET scans and cerebrospinal fluid analysis.
C2N's diagnostic approach is based on high-resolution mass spectrometry to measure the concentration of specific proteins and peptides in the blood, which are then analyzed using proprietary algorithms to predict the likelihood of Alzheimer's disease pathology. This technology aims to facilitate earlier and more accurate diagnosis, which is critical for timely intervention and management of the disease.
The company operates in the clinical diagnostics market and has secured partnerships to expand its reach, such as a multi-year agreement with Unilabs for the exclusive distribution of its Precivity tests in Europe. C2N has also achieved regulatory milestones, including medical device certification from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for its PrecivityAD2 blood test. The company is also developing a more comprehensive Brain Health Panel to assess multiple indicators of Alzheimer's and other neurological disorders.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2007
- Headquarters
- St. Louis, United States
- Employees
- 112
- Open positions
- None listed
- Dealroom signal
- 83.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, Woman Founder, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Mar 2025 | $0 | — | Samsung Bioepis · Samsung BioLogics · Samsung Ventures | ↗ |
| LATE VCOther financing | Sep 2024 | $7M | $75M | Alzheimer's Drug Discovery Foundation | ↗ |
Growth signals
Latest recorded traffic for C2N Diagnostics is 7.3K monthly website visits, up 32.7% over the last three months. C2N Diagnostics's team grew 31.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
GHR Foundation
Alzheimer's Drug Discovery Foundation
Series A1 investor entered at this stage
Eisai
Series B and later3 investors entered at this stage
Samsung Bioepis
Samsung BioLogics
Samsung Ventures
Other known investors1 additional known investor
Washington University in St. Louis
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about C2N Diagnostics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See C2N Diagnostics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.